Latest research
Latest corporate research
Latest tax advantaged reviews
Subscribe to our latest research
What we do
Investment research services
Tax enhanced research services
Bespoke consulting services
About
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
Our team
News & events
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
×
Latest corporate investment research
Detailed company analysis created specifically for investors
Latest tax advantaged research
Product reports for investors and advisors
Latest published research
NB Private Equity Partners
2025 CMD: good returns from low-risk PE model
3rd Dec 2025
Real Estate Credit Investments (RECI)
Investor Day: opportunities aplenty
2nd Dec 2025
Services for corporates
Investment research & analysis
Detailed company analysis created specifically for investors
Bespoke valuation services
Bespoke valuation services
Services for clients with specific needs
Services for funds
Tax advantaged research
Product reports for investors and advisors.
About
About Hardman & Co.
We are the longest-established commissioned research provider.
Insights
Group
Created with Sketch.
Podcasts
Group
Created with Sketch.
Videos
Group
Created with Sketch.
Events
Group
Created with Sketch.
See all news
Group
Created with Sketch.
Podcast
The EIS Navigator
Latest Episode
125: EIS and VC Basics: How venture capital exits work in EIS & VCTs | Kealan Doyle of Symvan Capital
Stay up-to-date with the latest research
Sign up to our newsletter
Our VCT forum is now available to watch on-demand for a limited time -
VCTs – Growing importance in taxing times: Watch on-demand now
Life Sciences research
Redx Pharma
Life Sciences
Back to the clinic
06 Sep 2018
Avacta Group plc
Life Sciences
Capital increase for further development
By
Dr Martin Hall
05 Sep 2018
Stay up-to-date with the latest research
Sign up to our newsletter
Bionomics Ltd
Life Sciences
FY’18 – focus on PTSD drug development
By
Dr Martin Hall
03 Sep 2018
Advanced Oncotherapy
Life Sciences
Treatment planning system agreement
By
Dr Martin Hall
29 Aug 2018
Oxford BioMedica
Life Sciences
Risk-sharing in cystic fibrosis gene-therapy
14 Aug 2018
Tissue Regenix
Life Sciences
1H’18 preview: organic plus inorganic growth
By
Dr Martin Hall
02 Aug 2018
Alliance Pharma Plc
Life Sciences
2018: a year of international progress
By
Dr Martin Hall
01 Aug 2018
Avacta Group plc
Life Sciences
Ground-breaking new drug conjugate platform
By
Dr Martin Hall
30 Jul 2018
Scancell Holdings
Life Sciences
SCIB1 – Strong survival data
By
Dr Martin Hall
18 Jul 2018
Allergy Therapeutics plc
Life Sciences
Steady performance in a tough market
By
Dr Martin Hall
13 Jul 2018
Evgen Pharma
Life Sciences
2018, a pivotal year
By
Dr Martin Hall
29 Jun 2018
Prev
1
...
12
13
14
15
16
...
22
Next
